Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study

BACKGROUND: Immune checkpoint inhibitors (ICIs)-based therapy, is regarded as one of the major breakthroughs in cancer treatment. However, it is challenging to accurately identify patients who may benefit from ICIs. Current biomarkers for predicting the efficacy of ICIs require pathological slides,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jianli, Sun, Zhixian, Yu, Yunfang, Yuan, Zhongyu, Lin, Ying, Tan, Yujie, Duan, Xiaohui, Yao, Herui, Wang, Ying, Liu, Jieqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230987/
https://www.ncbi.nlm.nih.gov/pubmed/37217246
http://dx.doi.org/10.1136/jitc-2022-006514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230987/
https://www.ncbi.nlm.nih.gov/pubmed/37217246
http://dx.doi.org/10.1136/jitc-2022-006514

Ejemplares similares